Fentanyl pain patches are recalled

Feb 18, 2008

The U.S. Food and Drug Administration announced the recall of Fentanyl transdermal system patches due to a potential safety hazard.

Actavis Inc. announced 14 lots of the patches sold nationwide might have a fold-over defect that could cause the patch to leak and expose patients or caregivers directly to the fentanyl gel. The FDA said Fentanyl is a potent opioid medication and exposure to the gel might lead to serious adverse events, including respiratory depression and possible overdose, which may be fatal.

Anyone who comes in contact with fentanyl gel should thoroughly rinse exposed skin with large amounts of water only; do not use soap, the company said.

Fentanyl transdermal patches are indicated for the management of persistent, moderate to severe chronic pain that requires continuous, around the clock opioid administration for an extended period of time and that cannot be managed by other means.

Complete recall information, including lot numbers, is available at
www.fda.gov/oc/po/firmrecalls/actavis02_08.html

Copyright 2008 by United Press International

Explore further: FDA warns of compounded drug recall by Texas firm

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

EU regulator: Morning-after pill OK for all women

58 minutes ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

5 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

5 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

18 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments : 0